In response to Ms. Gladu's comment, my understanding is that unlike the hookworm example, it is the same active ingredient in both of the alternative medicines.
I do want to say that the Government of Canada is clearly committed to ensuring that Canadians have access to safe, effective, and affordable medicines. Again, this drug has always been accessed through the SAP, the special access program. If the committee wants to do a big review of the SAP, that's a different topic altogether, but it continues to be available through SAP.
A physician has to request it and make the case on behalf of their patient. There's really nothing different, except that the alternative drug is now available without going through the SAP. It's more expensive, but, as I said, there is active work under way to reduce the price of it.
I don't know what more there is to study here. The drug is still available to patients if their physicians make the case for it and represent for their patients through the SAP, just as they have always been doing. I really don't see the need for this particular motion, and I won't be supporting it.